Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Haas T, Spielmann N, Restin T, Schmidt AR, Schmugge M, Cushing MM. Economic aspects of intraoperative coagulation management targeting higher fibrinogen concentrations during major craniosynostosis surgery. Paediatr Anaesth. 2016;26(1):77-83.

D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JM, MacDonald TY, Noorzad Z, et al. Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. Hum Pathol. 2016;58:54-61.

Sadimin ET, Khani F, Diolombi M, Meliti A, Epstein JI. Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies. Am J Surg Pathol. 2016;40(12):1686-1692.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7(45):72593-72607.

Marin EP, József L, Di Lorenzo A, Held KF, Luciano AK, Melendez J, et al. The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics. Arterioscler Thromb Vasc Biol. 2016;36(2):370-9.

Sboner A, Elemento O. A primer on precision medicine informatics. Brief Bioinform. 2016;17(1):145-53.

Lee SS, Tyler JK. Physiology: Stressed-out chromatin promotes longevity. Nature. 2016;534(7609):625-6.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi H-, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243-53.

Yi J, Humphries R, Doerr L, Jerris RC, Westblade LF. Bergeyella zoohelcum Associated with Abscess and Cellulitis After a Dog Bite. Pediatr Infect Dis J. 2016;35(2):214-6.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, et al. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016;22(4):935-47.